Imatinib for systemic mast-cell disease

Animesh D Pardanani, M. Elliott, T. Reeder, C. Y. Li, E. J. Baxter, N. C P Cross, Ayalew Tefferi

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

Imatinib has shown to be effective against malignant disease driven by ckit. We prospectively treated 12 adults with symptomatic systemic mast-cell disease at a dose of either 100 mg or 400 mg per day. Of the ten patients who we could assess for response, five (50%) had a measurable response to the drug, four of whom had important mast-cell cytoreduction and two who had complete clinical and histological remission. In the five patients with eosinophilia, three had complete clinical and haematological remission. The other two, who did not respond to treatment, were the only patients with the ckit D816V mutation. Our results suggest that imatinib either inhibits the growth-promoting role of wild type ckit, or targets an oncogenic kinase.

Original languageEnglish (US)
Pages (from-to)535-537
Number of pages3
JournalLancet
Volume362
Issue number9383
DOIs
StatePublished - Aug 16 2003

Fingerprint

Systemic Mastocytosis
Eosinophilia
Mast Cells
Phosphotransferases
Mutation
Growth
Pharmaceutical Preparations
Imatinib Mesylate
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pardanani, A. D., Elliott, M., Reeder, T., Li, C. Y., Baxter, E. J., Cross, N. C. P., & Tefferi, A. (2003). Imatinib for systemic mast-cell disease. Lancet, 362(9383), 535-537. https://doi.org/10.1016/S0140-6736(03)14115-3

Imatinib for systemic mast-cell disease. / Pardanani, Animesh D; Elliott, M.; Reeder, T.; Li, C. Y.; Baxter, E. J.; Cross, N. C P; Tefferi, Ayalew.

In: Lancet, Vol. 362, No. 9383, 16.08.2003, p. 535-537.

Research output: Contribution to journalArticle

Pardanani, AD, Elliott, M, Reeder, T, Li, CY, Baxter, EJ, Cross, NCP & Tefferi, A 2003, 'Imatinib for systemic mast-cell disease', Lancet, vol. 362, no. 9383, pp. 535-537. https://doi.org/10.1016/S0140-6736(03)14115-3
Pardanani AD, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NCP et al. Imatinib for systemic mast-cell disease. Lancet. 2003 Aug 16;362(9383):535-537. https://doi.org/10.1016/S0140-6736(03)14115-3
Pardanani, Animesh D ; Elliott, M. ; Reeder, T. ; Li, C. Y. ; Baxter, E. J. ; Cross, N. C P ; Tefferi, Ayalew. / Imatinib for systemic mast-cell disease. In: Lancet. 2003 ; Vol. 362, No. 9383. pp. 535-537.
@article{33c268cf64cd4e8799bc1320ad8ffbf6,
title = "Imatinib for systemic mast-cell disease",
abstract = "Imatinib has shown to be effective against malignant disease driven by ckit. We prospectively treated 12 adults with symptomatic systemic mast-cell disease at a dose of either 100 mg or 400 mg per day. Of the ten patients who we could assess for response, five (50{\%}) had a measurable response to the drug, four of whom had important mast-cell cytoreduction and two who had complete clinical and histological remission. In the five patients with eosinophilia, three had complete clinical and haematological remission. The other two, who did not respond to treatment, were the only patients with the ckit D816V mutation. Our results suggest that imatinib either inhibits the growth-promoting role of wild type ckit, or targets an oncogenic kinase.",
author = "Pardanani, {Animesh D} and M. Elliott and T. Reeder and Li, {C. Y.} and Baxter, {E. J.} and Cross, {N. C P} and Ayalew Tefferi",
year = "2003",
month = "8",
day = "16",
doi = "10.1016/S0140-6736(03)14115-3",
language = "English (US)",
volume = "362",
pages = "535--537",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9383",

}

TY - JOUR

T1 - Imatinib for systemic mast-cell disease

AU - Pardanani, Animesh D

AU - Elliott, M.

AU - Reeder, T.

AU - Li, C. Y.

AU - Baxter, E. J.

AU - Cross, N. C P

AU - Tefferi, Ayalew

PY - 2003/8/16

Y1 - 2003/8/16

N2 - Imatinib has shown to be effective against malignant disease driven by ckit. We prospectively treated 12 adults with symptomatic systemic mast-cell disease at a dose of either 100 mg or 400 mg per day. Of the ten patients who we could assess for response, five (50%) had a measurable response to the drug, four of whom had important mast-cell cytoreduction and two who had complete clinical and histological remission. In the five patients with eosinophilia, three had complete clinical and haematological remission. The other two, who did not respond to treatment, were the only patients with the ckit D816V mutation. Our results suggest that imatinib either inhibits the growth-promoting role of wild type ckit, or targets an oncogenic kinase.

AB - Imatinib has shown to be effective against malignant disease driven by ckit. We prospectively treated 12 adults with symptomatic systemic mast-cell disease at a dose of either 100 mg or 400 mg per day. Of the ten patients who we could assess for response, five (50%) had a measurable response to the drug, four of whom had important mast-cell cytoreduction and two who had complete clinical and histological remission. In the five patients with eosinophilia, three had complete clinical and haematological remission. The other two, who did not respond to treatment, were the only patients with the ckit D816V mutation. Our results suggest that imatinib either inhibits the growth-promoting role of wild type ckit, or targets an oncogenic kinase.

UR - http://www.scopus.com/inward/record.url?scp=0041656424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041656424&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(03)14115-3

DO - 10.1016/S0140-6736(03)14115-3

M3 - Article

VL - 362

SP - 535

EP - 537

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9383

ER -